Jump to content

Adrenergic receptor

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 146.9.22.63 (talk) at 19:23, 18 November 2007. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Epinephrine
Norepinephrine

The adrenergic receptors (or adrenoceptors) are a class of G protein-coupled receptors that are targets of the catecholamines. Adrenergic receptors specifically bind their endogenous ligands, the catecholamines adrenaline and noradrenaline (called epinephrine and norepinephrine in the United States), and are activated by these.

Many cells possess these receptors, and the binding of an agonist will generally cause a sympathetic response (ie the fight-or-flight response). For instance, the heart rate will increase and the pupils will dilate, energy will be mobilized, and blood flow diverted from other organs to skeletal muscle.(Note: Sympathetic activity will result in vasodilation of coronary arteries via the beta-2 beta-1?? adrenergic receptors.)

Subtypes

The mechanism of adrenergic receptors. Adrenaline or noradrenaline are receptor ligands to either α1, α2 or β-adrenergic receptors. α1 couples to Gq, which results in incerased intracellular Ca2+ which results in e.g. smooth muscle contraction. α2, on the other hand, couples to Gi, which causes a decrease of cAMP activity, resulting in e.g. smooth muscle contraction. β receptors couple to Gs, and increases intracellular cAMP activity, resulting in e.g. heart muscle contraction, smooth muscle relaxation and glycogenolysis.

There are several types of adrenergic receptors, but there are two main groups: α-Adrenergic and β-Adrenergic.

Comparison

Receptor type Agonist potency order Selected action
of agonist
Mechanism Agonists Antagonists
α1:
ADRA1A, ADRA1B, ADRA1D
noradrenaline≥ adrenaline >> isoprenaline smooth muscle contraction Gq: phospholipase C (PLC) activated, IP3 and calcium up noradrenaline
phenylephrine
methoxamine
Cirazoline
(Alpha blockers)
phenoxybenzamine
phentolamine
prazosin
tamsulosin
terazosin
α2:
ADRA2A, ADRA2B, ADRA2C
adrenaline > noradrenaline >> isoprenaline smooth muscle contraction Gi: adenylate cyclase inactivated, cAMP down clonidine
lofexidine
xylazine
Tizanidine
Guanfacine
(Alpha blockers)
yohimbine
β1:
isoprenaline > noradrenaline > adrenaline heart muscle contraction Gs: adenylate cyclase activated, cAMP up noradrenaline
isoprenaline
dobutamine
(Beta blockers)
metoprolol
atenolol
β2:
isoprenaline > adrenaline > noradrenaline smooth muscle relaxation Gs: adenylate cyclase activated, cAMP up (Short/long)
salbutamol (albuterol in USA)
bitolterol mesylate
formoterol
isoproterenol
levalbuterol
metaproterenol
salmeterol
terbutaline
(Beta blockers)
butoxamine
propranolol
ritodrine
β3:
isoprenaline > noradrenaline = adrenaline Enhance lipolysis Gs: adenylate cyclase activated, cAMP up L-796568
CL 316,243
LY 368842
Ro 40-2148
(Beta blockers)
SR 59230A

The absence of "ADRA1C" is intentional. At one time, there was a subtype known as C, but was found to be one of the previously discovered subtypes. To avoid confusion, it was decided that there would never be a C subtype again and so if any new subtypes were discovered, naming would start with D.

α receptors

α receptors have several functions in common, but also individual effects. Common effects include:

α1 receptor

Specific actions of the α1 receptor include:

α2 receptor

There are 3 highly homologous subtypes of α2 receptors: α2A, α2Β, and α2C.

Specific actions of the α2 receptor include:

β receptors

As with α receptors, there are common actions of all β receptors, in addition to specific actions of each subtype. Common actions include:

β1 receptor

Specific actions of the β1 receptor include:

β2 receptor

The 3D crystallographic structure of the β2-adrenergic receptor has been determined (PDB: 2R4R​, 2R4S​, 2RH1​).[4][5][6]

Specific actions of the β2 receptor include:

Muscular system

Circulatory system

digestive system

Other

β3 receptor

Specific actions of the β3 receptor include:

Diagrams

File:G protein signal transduction (epinephrin pathway).png
Epinephrine binds its receptor, that associates with an heterotrimeric G protein. The G protein associates with adenylate cyclase that converts ATP to cAMP, spreading the signal (more details...)

See also

References

  1. ^ a b c d e f g h i j k l m n o p q r s t u v w Fitzpatrick, David; Purves, Dale; Augustine, George (2004). "Table 20:2". Neuroscience (Third Edition ed.). Sunderland, Mass: Sinauer. ISBN 0-87893-725-0. {{cite book}}: |edition= has extra text (help); Cite has empty unknown parameter: |1= (help)CS1 maint: multiple names: authors list (link)
  2. ^ Chou EC, Capello SA, Levin RM, Longhurst PA (2003). "Excitatory alpha1-adrenergic receptors predominate over inhibitory beta-receptors in rabbit dorsal detrusor". J. Urol. 170 (6 Pt 1): 2503–7. doi:10.1097/01.ju.0000094184.97133.69. PMID 14634460.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Wright EE, Simpson ER (1981). "Inhibition of the lipolytic action of beta-adrenergic agonists in human adipocytes by alpha-adrenergic agonists". J. Lipid Res. 22 (8): 1265–70. PMID 6119348.
  4. ^ Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala V, Sanishvili R, Fischetti RF, Schertler GFX, Weis WI, Kobilka BK (2007). "Crystal Structure of the Human β2-Adrenergic G-Protein-Coupled Receptor". Nature. 450: in press. doi:10.1038/nature06325. PMID 17952055.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC (2007). "High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein Coupled Receptor". Science. 318: in press. doi:10.1126/science.1150577. PMID 17962520.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK (2007). "GPCR Engineering Yields High-Resolution Structural Insights into β2 Adrenergic Receptor Function". Science. 318: in press. doi:10.1126/science.1150609. PMID 17962519.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Trovik TS, Vaartun A, Jorde R, Sager G (1995). "Dysfunction in the beta 2-adrenergic signal pathway in patients with insulin dependent diabetes mellitus (IDDM) and unawareness of hypoglycaemia". Eur. J. Clin. Pharmacol. 48 (5): 327–32. PMID 8641318.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Further reading

  • Rang HP, Dale MM, Ritter JM, Moore PK (2003). "Ch. 11". Pharmacology. Elsevier Churchill Livingstone. ISBN 0-443-07145-4. {{cite book}}: Cite has empty unknown parameters: |coauthors= and |month= (help)CS1 maint: multiple names: authors list (link)
  • Rang HP, Dale MM, Ritter JM, Flower RJ (2007). "Ch. 11". Rang and Dale's Pharmacology. Elsevier Churchill Livingstone. pp. 169–170. ISBN 0-443-06911-5. {{cite book}}: Cite has empty unknown parameters: |coauthors= and |month= (help)CS1 maint: multiple names: authors list (link)


Template:Adrenergic Agonists